Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes ...
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema ...
The combination of cagrilintide 2.4 mg and semaglutide 2.4 mg was superior to semaglutide alone for weight loss and HbA1c ...
Once-weekly CagriSema significantly reduced HbA1c and body weight vs semaglutide in patients with type 2 diabetes in the REIMAGINE 2 trial.
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% ...
Obesity and weight management have become central topics in healthcare, with millions seeking effective solutions to achieve sustainable results. Among the most talked-about medications today are ...
Topline results from the REIMAGINE 2 trial involving 2,728 adults with type 2 diabetes inadequately controlled on metformin ...
FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits. There are differences, however.
Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and ...
In October 2025, Skye reported top-line 26-week data from CBeyond showing that the nimacimab and semaglutide combination cohort achieved clinically meaningful weight loss compared with semaglutide ...